MedTrace Logo

Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren

NCT02353663 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1023

Last updated 2016-04-06

No results posted yet for this study

Summary

Rheumatic heart disease remains a major challenge in low and middle income countries. Early detection of clinically silent valvular lesions by screening echocardiography allows timely implementation of secondary antibiotic prevention, and may prevent progression of disease to severe valvular damage and heart failure. The objective of the study is to assess the prevalence of rheumatic heart disease among schoolchildren in Arequipa, Peru. Subsequently, the investigators will evaluate progression of disease in children with early stages of subclinical rheumatic heart disease.

The investigators will perform a population-based observational survey for rheumatic heart disease using portable echocardiography among schoolchildren aged 5 to 16 years from randomly selected public and private schools. Rheumatic heart disease will be documented both according to the modified World Health Organization definition and the echocardiographic criteria suggested by the World Heart Federation.

Conditions

  • Rheumatic Heart Disease
  • Acute Rheumatic Fever

Interventions

OTHER

Echocardiography

Echocardiography examination

Sponsors & Collaborators

  • Instituto de Cardiología Paredes-Horna, Arequipa

    collaborator UNKNOWN

  • Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Thomas Pilgrim, MD · Bern University Hospital

Eligibility

Min Age
5 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-12-31
Completion
2015-07-31

Countries

  • Peru
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02353663 on ClinicalTrials.gov